Renal cell carcinoma recurrence after nephrectomy for localized disease: Predicting survival from time of recurrence

Journal of Clinical Oncology

Volumn 24, Issue 19, 2006, Pages 3101-3106

  Eggener, Scott E ^a   Yossepowitch, Ofer ^a   Pettus, Joseph A ^a   Snyder, Mark E ^a   Motzer, Robert J ^a   Russo, Paul ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; HEMOGLOBIN; LACTATE DEHYDROGENASE; TUMOR MARKER;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL TIME; AGED; CANCER STAGING; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33745984492     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.8280     Document Type: Article

References (27)

1. Frank I, Blute ML, Leibovich BC, et al: Independent validation of the 2002 American Joint Committee on Cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 173:1889-1892, 2005
2. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al: Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23:832-841, 2005
3. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540, 1999
4. Cindolo L, Patard JJ, Chiodini P, et al: Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy. Cancer 104:1362-1371, 2005
5. Kattan MW, Reuter V, Motzer RJ, et al: A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166:63-67, 2001
6. Zisman A, Pantuck AJ, Wieder J, et al: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20:4559-4566, 2002
7. Sorbellini M, Kattan MW, Snyder ME, et al: A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173:48-51, 2005
8. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48:7310-7313, 1988
9. Motzer RJ, Bacik J, Mariani T, et al: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20:2376-2381, 2002
10. Motzer RJ, Bacik J, Schwartz LH, et al: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-463, 2004
11. Motzer RJ, Bacik J, Murphy BA, et al: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296, 2002
12. Wehle MJ, Thiel DD, Petrou SP, et al: Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. Urology 64:49-52, 2004
13. Ogan K, Cadeddu JA: Minimally invasive management of the small renal tumor: Review of laparoscopic partial nephrectomy and ablative techniques. J Endourol 16:635-643, 2002
14. Greene F, Page D, Fleming I, et al: AJCC Cancer Staging Manual (ed 6). New York, NY, Springer-Verlag, 2002
15. Orrell DH: Albumin as an aid to the interpretation of serum calcium. Clin Chim Acta 35:483-489, 1971
16. Yates JW, Chalmer B, McKegney FP: Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45:2220-2224, 1980
17. Patard JJ, Kim HL, Lam JS, et al: Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: An international multicenter study. J Clin Oncol 22:3316-3322, 2004
18. Frank I, Blute ML, Cheville JC, et al: A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol 170:2225-2232, 2003
19. Stephenson AJ, Chetner MP, Rourke K, et al: Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 172:58-62, 2004
20. Kozlowski JM: Management of distant solitary recurrence in the patient with renal cancer: Contralateral kidney and other sites. Urol Clin North Am 21:601-624, 1994
21. Bukowski RM: Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 19:148-154, 2001
22. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24, 2006
23. Kim HL, Belldegrun AS, Freitas DG, et al: Paraneoplastic signs and symptoms of renal cell carcinoma: Implications for prognosis. J Urol 170:1742-1746, 2003
24. O'Keefe SC, Marshall FF, Issa MM, et al: Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J Urol 168:1378-1380, 2002
25. Kim HL, Seligson D, Liu X, et al: Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 173:1496-1501, 2005
26. Lam JS, Shvarts O, Leppert JT, et al: Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 174:466-472, 2005
27. Leibovich BC, Cheville JC, Lohse CM, et al: A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. J Urol 174:1759-1763, 2005